Your session is about to expire
← Back to Search
Unknown
HRS-3738 for Non-Hodgkin's Lymphoma and Multiple Myeloma
Phase 1
Recruiting
Research Sponsored by Jiangsu HengRui Medicine Co., Ltd.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from day 1 to 30 days after last dose
Awards & highlights
No Placebo-Only Group
Summary
This study is an open-label, multicenter Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics and efficacy of HRS-3738 in patients with recurrent and refractory Non-Hodgkin's lymphoma and multiple myeloma.
Eligible Conditions
- Non-Hodgkin's Lymphoma and Multiple Myeloma
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ from day 1 to 30 days after last dose
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from day 1 to 30 days after last dose
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Maximum tolerated dose (MTD)
RP2D
Secondary study objectives
AUC
CL/F
Cmax
+10 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: HRS-3738Experimental Treatment1 Intervention
In dose Escalation:
HRS-3738 will be taken in oral. Seven dose levels are preset.
In dose Expansion:
2 to 3 dose cohorts will be selected for dose expansion stage.
In indication Expansion:
Indications will be selected to evaluate preliminary efficacy.
Find a Location
Who is running the clinical trial?
Jiangsu HengRui Medicine Co., Ltd.Lead Sponsor
648 Previous Clinical Trials
99,674 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger